MedTrace Logo

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

NCT04198922 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-11-05

No results posted yet for this study

Summary

This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Conditions

  • Recurrent Moderate-Severe Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphoid Cell Neoplasm

Interventions

DRUG

Acalabrutinib

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Stephanie Lee, MD, MPH · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2025-09-29
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04198922 on ClinicalTrials.gov